Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205550 | 0.92 | HTR6 (0.77) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3206031 | 0.87 | HTR6 (0.76) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3622671 | 0.86 | HTR6 (0.78) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3208702 | 0.84 | HTR6 (0.76) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3216224 | 0.83 | HTR6 (1.00) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3212921 | 0.83 | HTR6 (1.00) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3202766 | 0.83 | HTR6 (0.77) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3204706 | 0.82 | HTR6 (0.67) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3622796 | 0.81 | HTR6 (0.62) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3213479 | 0.81 | HTR6 (1.00) | HTR6CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041669-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-02-18 | — | — | US | claimed |
| EP-2121602-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2009-11-25 | — | — | EP | claimed |
| WO-2008084491-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-07-17 | — | — | WO | claimed |
| EP-2121602-B1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-03-18 | — | — | EP | disclosed |
| US-20100041669-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041669-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR1A | HTR6 1/4885CYP3A4 224/4885CYP2D6 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.